SEC Tracker
Get the app
ZVRA · XBRL financial data

Zevra Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (ZVRA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cost of revenueyear only———————————
Selling, general and administrative14,657*9,93112,60416,20816,125*19,54520,78216,93520,354*20,78316,55919,130
Operating income (loss)(14,671)*(20,486)(23,795)(27,306)(15,416)*(5,362)(71,039)4,1439,315*52,14616,77711,580
Interest expense756*7352,1102,3122,194*1,9692,0092,0511,948*1,71100
Income tax expense (benefit)0*(70)70015,371*1,1822,199(433)501*6,9144,042510
Net income (loss)(15,153)*(16,622)(19,925)(33,225)(35,739)*(3,099)74,707(544)12,165*37,8908,75219,208
Earnings per share, basic USD per share(0.39)*(0.40)(0.48)(0.69)(0.67)*(0.06)1.24(0.01)0.22*0.620.140.31
Earnings per share, diluted USD per share——(0.48)(0.69)—(0.06)1.21(0.01)0.19*0.600.140.26
Weighted average shares, basic thousands of shares38,682*41,77941,89947,80953,422*54,09654,78155,95256,385*58,40659,15659,407
Weighted average shares, diluted thousands of shares——41,89947,809—54,09656,32555,95262,600*60,23061,33761,732

Balance sheet

CSV

Fiscal quarters (ZVRA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Cash and cash equivalents43,04942,84939,26054,03933,78537,34047,71254,43962,40695,595145,321122,148
Marketable securities24,6889,8689,99835,33735,71125,291154,899145,070128,605105,02176,24973,420
Marketable securities, non-current0——6,1056,0106,09115,08930,86547,87936,14538,60975,323
Accounts receivable16,119———10,176———————
Inventory9,841———1,9702,5591,1081,3671,7402,3102,4493,070
Prepaid and other current assets1,8241,8682,6862,2764,0523,7664,3527,3986,9984,9444,7947,257
Total current assets86,93862,89060,89199,44286,02781,573226,337225,115223,007229,968251,302225,838
Property and equipment, net736695678607356422599488489430641816
Right-of-use asset7901,0869118206571,6361,4961,3371,2121,0871,6671,423
Goodwill4,7014,7014,7014,7014,7014,7014,7014,7014,7014,7014,7014,701
Total assets172,327151,283144,408191,551178,127172,708256,277270,116284,731278,579302,712313,575
Accounts payable13,987———13,075———2,478———
Total current liabilities73,72029,90930,44934,48134,06526,97628,83226,11239,27747,02848,63241,369
Long-term debt5,066—58,32858,90459,50460,09060,69261,31061,928000
Lease liability, non-current4567055444833721,1581,059966859741870602
Total liabilities110,463102,465111,930121,781138,461131,685139,047136,951130,07472,77585,06074,652
Accumulated deficit(399,778)(416,400)(436,325)(469,550)(505,289)(508,388)(433,681)(434,225)(422,060)(384,170)(375,418)(356,210)
Total stockholders' equity61,86448,81832,47869,77039,66641,023117,230133,165154,657205,804217,652238,923
Total liabilities and equity172,327151,283144,408191,551178,127172,708256,277270,116284,731278,579302,712313,575
Common shares outstanding (cover page) thousands of shares43,42641,85352,61853,37654,11654,68056,13556,29858,71259,11559,38459,505

Cash flows

CSV

Fiscal quarters (ZVRA's year ends in late December)

In thousands of dollarsDec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026Sep 30, 2026
Net income (loss)(15,153)*(16,622)(19,925)(33,225)(35,739)*(3,099)74,707(544)12,165*37,8908,75219,208
Stock-based compensation2,873*2,1192,632*6,137*4,018*3,1152,464*2,771*4,284*3,1052,969*2,672*
Depreciation and amortization787*1,5621,562*1,617*1,648*1,6491,651*392*362*368364*378*
Net cash from operating activities(16,158)*(16,165)(19,109)*(18,141)*(16,250)*(8,222)(3,601)*4,709*5,516*6,14217,032*10,047*
Purchases of property and equipment72*00*0*0*99213*554*(31)*35217*238*
Net cash from investing activities10,585*14,793(129)*(31,354)*(5,471)*10,54211,934*(4,576)*227*79,61831,451*(34,851)*
Proceeds from issuing common stock6,106*1,217(71)*64,673*(1,303)*0——0*———
Share repurchases0*00*0*0*———————
Net cash from financing activities5,004*1,21715,330*64,765*796*1,6071,381*6,530*2,546*(52,804)1,585*1,551*
Net change in cash(220)*(200)(3,589)*14,779*(20,254)*3,55510,372*6,727*7,967*33,18949,726*(23,173)*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Zevra Therapeutics122,14837,75610,047*59.5M— 10-QSep 30, 2026
Theravance Biopharma219,76620,731(6,965)*51.9M55.7 quarters 10-QJun 30, 2026
aTYR PHARMA16,160not reported(9,351)*98.1M6.1 quarters 10-QJun 30, 2026
Arvinas88,000500(10,400)*65.5M13.0 quarters 10-QSep 30, 2026
Arbutus Biopharma19,1711,014(6,018)*197.8M15.4 quarters 10-QJun 30, 2026
Myriad Genetics115,200190,700(8,300)*95.6M13.9 quarters 10-QJun 30, 2026
CytoDyn16,359not reported(7,726)1.5B2.1 quarters 10-QAug 31, 2026
Kura Oncology70,24220,874(62,549)*89.0M8.3 quarters 10-QJun 30, 2026
KalVista Pharmaceuticals213,76840,863(14,455)53.2M19.7 quarters 10-QMar 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.